The Chinese government halted the recommendation of an herbal supplement used as a traditional Chinese treatment for mild cases of COVID-19.

AstraZeneca’s Chinese operation is under intense scrutiny by the National Healthcare Security Administration of China over concerns about suspected medical insurance fraud perpetrated by company employees.

Drugmakers agreed to cut prices by around 50% on average for more than 100 medicines in order to have them included in China’s state medical insurance scheme from March, potentially heralding a massive leap in sales.